Could a nerve zap stop cancer wasting? early trial tests device for cachexia

NCT ID NCT07700212

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This early-phase trial tests whether a device that blocks signals from the vagus nerve can safely help patients with metastatic pancreatic cancer who are experiencing severe weight loss (cachexia). The device is placed on the skin over the nerve and is used alongside chemotherapy. The main goal is to check for side effects and see if it might help control the wasting process.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
OnVagus device (transcutaneous low-frequency vagal nerve blockade)
What this could lead to
If safe and effective, this approach could offer a new way to prevent or reverse cancer-related wasting, improving strength and quality of life for patients.
What could go wrong
This is a very early, small phase 1 trial focused on safety, not proof of benefit. The device may cause side effects or fail to stop weight loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UT MD Anderson

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.